These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

493 related items for PubMed ID: 23720945

  • 21. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.
    Warnke C, Mausberg AK, Stettner M, Dehmel T, Nekrich L, Meyer zu Horste G, Hartung HP, Fogdell-Hahn A, Adams O, Kieseier BC.
    Neurology; 2013 Oct 15; 81(16):1400-8. PubMed ID: 24049136
    [Abstract] [Full Text] [Related]

  • 22. Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report.
    Puig-Casadevall M, Álvarez-Bravo G, Varela AQ, Robles-Cedeño R, Sànchez Cirera L, Miguela A, Laguillo G, Montalban X, Hauser SL, Ramió-Torrentà L.
    Eur J Neurol; 2023 Oct 15; 30(10):3357-3361. PubMed ID: 37485841
    [Abstract] [Full Text] [Related]

  • 23. JCV-negative natalizumab-associated progressive multifocal leukoencephalopathy: a clinico-radiological diagnosis.
    Travasarou M, Marousi S, Papageorgiou E, Karageorgiou CE.
    Clin Neurol Neurosurg; 2013 Jun 15; 115(6):827-9. PubMed ID: 22920632
    [No Abstract] [Full Text] [Related]

  • 24. Multiple sclerosis, natalizumab, and PML: helping patients decide.
    Rudick RA.
    Cleve Clin J Med; 2011 Nov 15; 78 Suppl 2():S18-23. PubMed ID: 22123928
    [Abstract] [Full Text] [Related]

  • 25. Transient punctuate enhancing lesions preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Taieb G, Renard D, Thouvenot E, Servillo G, Castelnovo G.
    J Neurol Sci; 2014 Nov 15; 346(1-2):364-5. PubMed ID: 25241939
    [No Abstract] [Full Text] [Related]

  • 26. Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
    Décard BF, Haghikia A, Tönnes C, Thöne J, Lukas C, Chan A, Gold R.
    Mult Scler; 2013 Feb 15; 19(2):249-51. PubMed ID: 22596228
    [Abstract] [Full Text] [Related]

  • 27. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
    Ziemssen T, Gass A, Wuerfel J, Bayas A, Tackenberg B, Limmroth V, Linker R, Mäurer M, Haas J, Stangel M, Meergans M, Harlin O, Hartung HP.
    BMC Neurol; 2016 Jul 12; 16():98. PubMed ID: 27405225
    [Abstract] [Full Text] [Related]

  • 28. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R, Mostosi C, Quivron B, Delberghe X, El Hafsi K, Lysandropoulos AP.
    Clin Ther; 2016 Mar 12; 38(3):670-5. PubMed ID: 26856928
    [Abstract] [Full Text] [Related]

  • 29. Deaths and disability from natalizumab are no longer tolerable: Commentary.
    Hutchinson M.
    Mult Scler; 2012 Aug 12; 18(8):1073. PubMed ID: 22807472
    [No Abstract] [Full Text] [Related]

  • 30. Natalizumab for multiple sclerosis: a complicated treatment.
    Keegan BM.
    Lancet Neurol; 2011 Aug 12; 10(8):677-8. PubMed ID: 21777819
    [No Abstract] [Full Text] [Related]

  • 31. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
    Wattjes MP, Richert ND, Killestein J, de Vos M, Sanchez E, Snaebjornsson P, Cadavid D, Barkhof F.
    Mult Scler; 2013 Dec 12; 19(14):1826-40. PubMed ID: 24192217
    [Abstract] [Full Text] [Related]

  • 32. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M, Plavina T, Khatri BO, Fox RJ, Goelz SE.
    Mult Scler; 2013 Jun 12; 19(7):912-9. PubMed ID: 23232602
    [Abstract] [Full Text] [Related]

  • 33. Interruption of natalizumab therapy for multiple sclerosis: what are the risks?
    Naismith RT, Bourdette D.
    Neurology; 2011 May 31; 76(22):1854-5. PubMed ID: 21543735
    [No Abstract] [Full Text] [Related]

  • 34. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
    Marousi S, Travasarou M, Karageorgiou CE, Gheuens S, Koralnik IJ.
    Neurology; 2012 Nov 20; 79(21):2160; author reply 2160. PubMed ID: 23170016
    [No Abstract] [Full Text] [Related]

  • 35. Natalizumab-associated progressive multifocal leukoencephalopathy.
    Cervera C.
    N Engl J Med; 2012 Aug 30; 367(9):871; author reply 872. PubMed ID: 22931328
    [No Abstract] [Full Text] [Related]

  • 36. Natalizumab-associated progressive multifocal leukoencephalopathy.
    Mancini N, Clementi M, Burioni R.
    N Engl J Med; 2012 Aug 30; 367(9):871-2; author reply 872. PubMed ID: 22931329
    [No Abstract] [Full Text] [Related]

  • 37. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.
    Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D.
    N Engl J Med; 2005 Jul 28; 353(4):375-81. PubMed ID: 15947078
    [Abstract] [Full Text] [Related]

  • 38. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.
    Kleinschmidt-DeMasters BK, Tyler KL.
    N Engl J Med; 2005 Jul 28; 353(4):369-74. PubMed ID: 15947079
    [Abstract] [Full Text] [Related]

  • 39. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
    Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC, Montalban X, Olsson T.
    Mult Scler; 2012 Feb 28; 18(2):143-52. PubMed ID: 22312009
    [Abstract] [Full Text] [Related]

  • 40. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.
    Schröder A, Lee DH, Hellwig K, Lukas C, Linker RA, Gold R.
    Arch Neurol; 2010 Nov 28; 67(11):1391-4. PubMed ID: 20625069
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.